



Meiji Animal Health Co., Ltd.

April 1, 2022

Notice Regarding Establishment of Meiji Animal Health Co., Ltd. and Start of Business

We are pleased to announce that Meiji Animal Health Co., Ltd., a new company assuming the responsibility for the Meiji Group's animal health business, was established and it started business on April 1, 2022.

Meiji Animal Health is a company established by splitting and succeeding the animal health businesses* from two operating companies of Meiji Holdings Co., Ltd.; KM Biologics Co., Ltd. (Headquarters: Kumamoto-shi, Kumamoto, President: Toshiaki Nagasato) and Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo, President: Daikichiro Kobayashi). The company aims at further enhancement and growth of the Meiji Group's animal health business. By integrating the business areas and product lines from KM Biologics and Meiji Seika Pharma, Meiji Animal Health enhances comprehensive platform for prevention and treatment of infectious disease in a wider range of animal species, and provides total solutions in infection control. Meiji Animal Health strives to be more beneficial to the users and to increase its presence in the animal health market in Japan.

Meiji Animal Health will protect animals through the provision of veterinary products mainly in the field of infectious disease, promote One Health Approach,** and contribute to stable supply and better productivity of reliable and safe livestock & aquatic products, as well as improvement of people's quality of life and spiritual richness brought by living with companion animals.

Overview of Meiji Animal Health Co., Ltd.

(1) Name Meiji Animal Health Co., Ltd.

(2) Address of head office
(3) Name of representative
1-6-1 Okubo, Kita-ku, Kumamoto-shi, Kumamoto, Japan
Kazuhiko Hirose (President and Representative Director)

(4) Details of business Marketing of veterinary products

(5) Paid in capital 100 million Japanese yen

(6) Date of establishment April 1, 2022

(7) Shareholding structure Meiji Seika Pharma Co., Ltd.: 49.7%

KM Biologics Co., Ltd.: 50.3%

(8) Number of employees 112

^{*} Excluding the production department of KM Biologics

^{**} An approach in which relevant parties work together to solve cross-sectoral issues related to human, animal, and environmental hygiene as measures against zoonoses, drug-resistant bacterial infections, etc.